Prognostic value and clinicopathologic significance of nm23 in various cancers: A systematic review and meta-analysis
- 1 December 2018
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in International Journal of Surgery
- Vol. 60, 257-265
- https://doi.org/10.1016/j.ijsu.2018.10.035
Abstract
Objective: Extensive studies have been carried out to investigate the association between nm23 expression and the prognosis and clinicopathologic significance of various tumors. Methods and materials: Eligible studies were searched from Embase, China National Knowledge Infrastructure (CNKI), PubMed and Web of Science up to May 2017. In this study, we calculated the pooled hazard ratios (HRs) with 95% confidence intervals (95% CIs) to determine the association between nm23 expression and the prognosis of various tumors. Results: A total of 49 studies were finally included in the meta-analysis. The pooled HRs were 2.00 (95% CIs: 1.44-2.78) for overall survival (OS), 1.23 (95% CIs: 1.04-1.46) for disease-specific survival or progression-free survival (DFS/PFS), and 2.21 (95% CIs: 1.38-3.57) for survival of recurrence-free survival or metastasis-free survival (RFS/MFS). Moreover, the results indicated that low nm23 expression was significantly correlated with the lymph node metastasis (P = 0.002). For the subgroup analysis, the expression of nm23 in patients at N0 stage was obviously higher than the patients with breast carcinoma at N1-N3 stage [Odds ratio (OR)= 2.07, 95% CI (1.31, 3.26), P = 0.002]. Moreover, the expression of nm23 in the patients at N0 stage was remarkably higher than those at N1-N3 stages in the Chinese patients with breast carcinoma and those with nasopharyngeal carcinoma (P < 0.05). Whereas, no statistical difference was noticed in the expression of nm23 in patients of various age, gender, T stage, histological degree, TNM stage, respectively (P > 0.05). Conclusion: Our study suggests that down-regulation of nm23 is related to poor prognosis in many cancers. The expression of nm23 in cancer tissues may serve as an important factor for evaluating the presence of lymph node metastasis.Keywords
Funding Information
- the Natural Science Foundation of Shanghai (14ZR1407900)
- The Foundation of Fudan University Shanghai cancer center (YJ201713)
This publication has 47 references indexed in Scilit:
- Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissueClinical Proteomics, 2012
- Nm23‐H1 nuclear expression is associated with a more favourable prognosis in laryngeal carcinoma: univariate and multivariate analysisHistopathology, 2012
- Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapyHead & Neck, 2010
- Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical ApplicationClinical Cancer Research, 2006
- Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome of patients with head and neck squamous-cell carcinoma treated with radical radiotherapyJournal of Clinical Pathology, 2006
- DNA Ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective studyZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- The Ras-like GTPase Gem is involved in cell shape remodelling and interacts with the novel kinesin-like protein KIF9The EMBO Journal, 2001
- Expression of nm23 in gastric carcinomaCancer, 1998
- A small GTP-binding protein is frequently overexpressed in peripheral blood mononuclear cells from patients with solid tumoursEuropean Journal of Cancer, 1994
- Reduced Expression of nm23 Is Associated with Metastasis of Human Gastric CarcinomasJapanese Journal of Cancer Research, 1993